Premium
Interleukin‐2—activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro
Author(s) -
Kruse Carol A.,
Mitchell Dawn H.,
Lillehei Kevin O.,
Johnson Stephen D.,
McCleary E. Larry,
Moore George E.,
Waldrop Sharon,
Mierau Gary W.
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19891015)64:8<1629::aid-cncr2820640813>3.0.co;2-d
Subject(s) - lymphokine activated killer cell , interleukin 2 , lymphokine , cytotoxic t cell , medicine , in vitro , immunology , ficoll , lymphocyte , microbiology and biotechnology , cd8 , peripheral blood mononuclear cell , cytokine , biology , antigen , interleukin 21 , biochemistry
Two preparations of human recombinant interleukin‐2 (rIL‐2)‐activated lymphocytes from patients harboring malignant brain tumors were characterized as autologous‐stimulated lymphocytes (ASL) and lymphokine‐activated killer (LAK) cells. ASL were generated from Ficoll‐Paque—isolated, nonadherent, defibrinated peripheral blood lymphocytes (PBL) that were stimulated overnight with phytohemagglutinin (PHA) and cultured with rIL‐2 (100 U/ml) for 10 days. LAK cells were produced by culturing all PBL in rIL‐2 (500 U/ml) for 4 days. In 4‐hour chromium release assays, LAK cells showed greater cytotoxicity than ASL against natural killer (NK)‐sensitive and NK‐resistant tumor cell lines; by 18 hours, the effectiveness of ASL equaled that of LAK cells. By electron microscopic study, PBL, LAK cells, and ASL showed differences. The helper/inducer to suppressor/cytotoxic ratio (T4+/T8+) of PBL, LAK cells, and ASL was 1.1:1, 1.0:1, and 0.4:1, respectively. ASL, when compared with PBL or LAK cells, have a significantly higher percentage of MO1+/DR+ and T8+/9.3+ subpopulations. ASL and LAK cells, used for the therapy of gliomas, are distinct.